News
Singapore’s Thomson Medical buys Vietnam’s FV Hospital
SGX Mainboard-listed healthcare group Thomson Medical Group (TMG) has agreed to acquire Vietnam's FV Hospital for up to $381.4 million,.
Kelun-Biotech Raises HK$1.26 Billion in Hong Kong IPO; Prices at Bottom of Range
Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) priced its Hong Kong initial public offering on Monday to raise HK$1.26 billion in net proceeds from the offering.
Wall Street Banks Court Sovereign Funds for Syngenta’s $9 Billion IPO
Wall Street banks are helping approach international investors for Syngenta Group's 65 billion yuan ($9 billion) initial public offering in Shanghai.
Novartis terminates its option agreement with BeiGene
BeiGene Switzerland and Novartis entered into a Mutual Termination and Release Agreement (the “Termination Agreement”) to mutually terminate the Option Agreement, effective immediately.
Chinese biopharmaceutical firm Pyrotech Therapeutics bags $97m in Series A round
Chinese biopharmaceutical firm Pyrotech Therapeutics has secured 700 million yuan ($97.2 million) in a Series A financing round co-led by state-owned investment firms SDIC Venture Capital and China Venture Capital, according to a company release on Monday
European Medicines Agency Accepts Astellas’ Marketing Authorization Application for Zolbetuximab
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the European Medicines Agency (EMA) has accepted for regulatory review the company's marketing authorization application (MAA) for zolbetuximab.
InnoCare and ArriVent Announce Clinical Development Collaboration
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases and ArriVent Biopharma, a clinical stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced a clinical development collaboration.
Harbour BioMed Announces 2023 Interim Results Positive Profit Alert with the Enhancement of Value Driven by Innovation
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology announces that, it is anticipated that the Company will record a significant increase in its revenue for the six months ended June 30, 2023.
HUTCHMED Announces Changes to Board of Directors and Technical Committee
Ms Ling Yang to replace Mr Lefei Sun as Non-executive Director; Professor Solange Peters appointed as Special Advisor to the Technical Committee
Novotech Announced as Finalist for Asia Pacific Cell & Gene Therapy CRO Excellence Awards 2023
Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities is a finalist in the Asia Pacific Cell & Gene Therapy Awards 2023.
